ArticleOncotarget2013
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Alexandra Canonici et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
85 papers cite itlatest 60 shown
this paperpooled ittrialcites it